It is well established that NSE and SE (all TGCT) are widely responsive to cisplatin-based therapy (Bosl and Motzer, 1997), so one wouldn’t expect the high presence of hMLH1 methylation in this tumour type. This evidence concerns the gene ENO2 and neoplasm.